Novo Nordisk A/S (ADR) 37.16bn 13.01bn 295.94bn 71.88k AbbVie Inc 55.53bn 5.08bn 309.55bn 50.00k Johnson & Johnson 87.70bn 14.77bn 342.03bn 131.90k Data as of Jan 15 2025. Currency figures normalised to Novo Nordisk A/S's reporting currency: US Dollar USD Institutional shareholders Top ...
Get Novo Nordisk A/S (NVO:NYSE) real-time stock quotes, news, price and financial information from CNBC.
NONOF Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -16.10% Novo Nordisk A/S price and volume Combination chart with 2 data series. Chart represents Novo Nordisk A/S price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y ...
1 tick value per share 0.01 USD Minimum contract size 0.01 share Commission No Minimum Price Fluctuation 0.01 USD Minimum step for increasing contract size 0.01 share Margin requirements to open a lock position * 0 Maximum Trade Size 1000
Latest Novo Nordisk A/S (NVON:MEX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Novo Nordisk announces positive topline results for amycretin study - share price rises. www.marketscreener.com/... Yesterday, 5:46 AM View GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study prudent 576 From a technical & public relations point of view, ...
Novo Nordisk A/S - share repurchase programmeJan. 20GL Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiationsJan. 17AQ Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence...
Everything is modelled in USD at current FX rates. Target Company: Custom Synergies ($m): 2025+ Recalculate This feature is only available to DRUGANALYST subscribers
Novo Nordisk A/S reported earnings per share of $ 0.83 in the last report, surpassing an estimated EPS of $ 0.77 by 7.79%. Report DateForecasted EPS Reported EPS (Surprise) Last Year's EPS EPS YoY Change May 2, 2024 $ 0.77 $ 0.83 (7.79%) $ 0.64 29.69% Jan 31, ...
Novo Nordisk also agreed to acquire the asset Ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences PTE., Ltd. in 2023. The purchase price of the asset acquisition was USD 800 million with additional contingent payments of USD ...